ImmunoPrecise Antibodies and Biotheus have collaborated to develop bispecific therapies for solid tumors. Biotheus will evaluate Talem Therapeutics’ AI-enhanced TATX-20 antibody asset to develop novel bispecific antibodies that target hypoxic solid tumors.
Bispecific antibodies simultaneously target two distinct tumor markers, potentially enhancing treatment efficacy and addressing the challenges of treating oxygen-deprived tumors.
Biotheus will leverage its antibody discovery and development expertise to engineer these novel bispecific antibodies. The collaboration aims to identify promising molecules for clinical trials, accelerating the development of groundbreaking cancer treatments.
Xiaolin Liu, CEO of Biotheus, highlights the potential of AI-informed molecules in developing novel bispecific antibodies with first-in-class potential, promising breakthrough therapies for cancer patients.
Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, emphasizes the collaboration’s potential to accelerate the creation of innovative cancer treatments by combining their AI-enhanced antibody discovery technology and Biotheus’s bispecific engineering expertise.
This agreement underscores the value of ImmunoPrecise Antibodies’ AI-driven assets and establishes a mutually beneficial partnership focused on transforming cancer therapeutics. The collaboration is expected to drive significant value for both companies and benefit patients seeking advanced treatment options.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
